ABCA3 gene — Drug Target
All drugs that target ABCA3 gene — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Phase 3 pipeline (1)
- MDR-101 · Medeor Therapeutics, Inc. · Gene therapy · Pulmonology / Rare Genetic Lung Disease
MDR-101 is a gene therapy that delivers a functional copy of the ABCA3 gene to restore surfactant production in patients with ABCA3-deficient interstitial lung disease.